Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer (CRC). This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates ranging from 22.2% to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival. However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of RAS mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.
No takes yet. Share an insight, caveat, or question.
Olatunji et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: